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Virus-directed enzyme prodrug therapy (VDEPT) utilising the bacterial enzyme nitroreductase delivered by a replication-defective
adenovirus vector to activate the prodrug CB1954 is a promising strategy currently undergoing clinical trials in patients with a range of
cancers. An understanding of the mechanism of tumour cell death induced by activated CB1954 will facilitate this clinical
development. Here, we report that activated CB1954 kills cells predominantly by caspase-dependent apoptosis. This may have
important implications for the generation of immune-mediated bystander effects. Further, the use of a replication-defective
adenovirus vector to deliver nitroreductase may negatively affect cellular apoptotic pathways stimulated by activated CB1954. Finally,
examination of nitroreductase/CB1954 in combination with conventional chemotherapy reveals a synergistic interaction with 5-
fluorouracil. These data will facilitate the further development and future clinical trial design of this novel therapy.
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Epithelial ovarian cancer is the leading cause of death from
gynaecological cancer with the majority of patients presenting with
advanced intraperitoneal disease and requiring chemotherapy. The
current standard treatment is a combination of carboplatin or
cisplatin with paclitaxel. However, 5-year survival remains poor at
25–30%. It is imperative therefore that novel treatments are
developed.
Chemotherapeutic drugs can kill cells by activating apoptotic
pathways and the exact mechanism by which this occurs is
currently under intense investigation. Initial studies revealed that
cytotoxic drugs can activate death receptor/caspase-8 signalling
pathways and this mechanism may be an essential factor in the
early phase of drug-induced cell death depending on the cell type
used (Friesen et al, 1996; Fulda et al, 1997, 1998a,b, 2000; Micheau
et al, 1997). However, not all cell types require death receptor–
ligand interaction for drugs to be effective (Gamen et al, 1997;
Eischen et al, 1997; Villunger et al, 1997; Tolomeo et al, 1998; Ruiz-
Ruiz and Lopez-Rivas, 1999). Recent studies have indicated that
caspase-8 can be activated independently of death receptor ligation
(Milner et al, 2002). Interestingly, different drugs may engage
distinct components of the apoptotic machinery (Milner et al,
2002). This is important since it may allow the use of different
drugs to form potentially synergistic combinations.
A novel approach to cancer therapy currently entering clinical
trials is Virus-Directed Enzyme Prodrug Therapy (VDEPT). This
utilises an adenovirus delivered enzyme, nitroreductase (NR), to
catalyse the conversion of a relatively nontoxic prodrug (CB1954)
into an extremely potent DNA cross-linking agent. Preclinical
studies have shown that adenoviral delivery of NR to a range of
human cancer cell lines sensitises them to CB1954 by 500–2000-
fold compared to the parental cell line (Weedon et al, 2000).
Further, in an in vivo xenograft model of peritoneal pancreatic
cancer (Suit 2), a doubling in median survival was seen in mice
treated with virus and CB1954 compared to controls (Po0.0001)
(Weedon et al, 2000).
In vitro cell mixing experiments using unmodified and NR-
expressing ovarian carcinoma cell lines have demonstrated
significant sensitisation (30–100-fold) of the total cell population
to CB1954 when only 5–10% of the cells express NR (McNeish et al,
1998). Similarly, in vivo in a human hepatoma murine xenograft
model, a significant antitumour effect and improved survival were
observed even when only 5% of cells expressed NR, confirming a
significant bystander effect (Djeha et al, 2000). Interestingly,
studies of other enzyme–prodrug combinations also suggest a
‘distant bystander effect’ thought to be a systemic immune-
mediated response to local tumour cell killing (Link et al, 1997).
Other potential advantages of the NR/CB1954 combination are the
ability to kill cells in a cell cycle-independent manner and the lack
of cross-resistance with other commonly used cytotoxic agents
(Bridgewater et al, 1995; Knox, 1998). A recent phase I clinical trial
has confirmed that CB1954 is a well-tolerated prodrug that can be
administered intravenously or intraperitoneally at doses sufficient
for a VDEPT approach to be feasible in the treatment of ovarian
cancer (Chung-Faye et al, 2001). A further clinical trial to assess
the safety, tolerability and transgene expression of a replication-
deficient adenovirus vector carrying the gene for nitroreductase is
ongoing. It is important, therefore, to investigate the mechanism Received 22 April 2003; revised 30 June 2003; accepted 1 July 2003
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sby which activated CB1954 kills NR-expressing cancer cells. This
will facilitate the further clinical development of this system in
enhancing distant bystander effects and in devising rational
combinations with conventional chemotherapeutic agents.
The aims of the current study are: (1) to determine the mode of
cell death initiated by activated CB1954, (2) to identify the
apoptotic pathways induced by activated CB1954 and in particular
to identify any requirement for caspase activation, and (3) to
assess the effect of CB1954 given in combination with a range of
other chemotherapeutic agents in order to identify mechanistically
synergistic drug combinations that may be utilised in future
clinical trials.
MATERIALS AND METHODS
Cells and cell culture
The human ovarian carcinoma cell line SKOV3 was maintained in
DME with HEPES, 10% FCS and supplemented with glutamine.
Stable NR-expressing SKOV3 cells (SKOV3NR) generated by
infection with a retrovirus vector carrying the gene for E. coli
bacterial nitroreductase were the kind gift of Dr PF Searle
(University of Birmingham, UK).
Detection of NR and caspases by Western blotting
Cells were harvested, washed once in ice-cold PBS, pelleted by
centrifugation and pellets lysed for 20min on ice. Samples were
pelleted at 13000rpm at 41C and lysates decanted and stored at
 701C. Protein concentrations of total cell lysates were determined
using a Biorad (Hercules, CA, USA) assay. Total cell lysate protein
(100mg) was separated by SDS–PAGE and electroblotted onto
nitrocellulose. Membranes were blocked with 5% milk in PBS–
Tween and then probed with either polyclonal nitroreductase
antibody 108B (kindly provided by Dr M Ford, Glaxo-Wellcome,
Stevenage, UK) diluted 1:20000, or polyclonal rabbit anti-caspase-
8 (a kind gift from Dr G Cohen, University of Leicester, UK; Sun
et al, 1999) diluted 1:3000, monoclonal mouse anti-caspase-9
(Calbiochem) diluted 1:100, polyclonal rabbit anti-caspase-3
(Pharmingen, San Diego, CA, USA) diluted 1:5000. Immune
complexes were detected with horseradish peroxidase-conjugated
secondary antibodies (anti-rabbit diluted 1:2000; anti-mouse
diluted 1:1000; Sigma, UK) and then visualised with ECL reagent
(Amersham, UK) and autoradiography.
Adenovirus infection of cells
SKOV3 cells were plated out at a density of 2 10
6 cellsml
 1 in
75cm
3 flasks and allowed to attach overnight. The medium was
removed and the cells were exposed to either RAd-NR, an E1-, E3-
deleted replication-defective adenovirus expressing bacterial NR
from the CMV promoter, or a control b-galactosidase-expressing
adenovirus (RAd35, kindly provided by Dr G Wilkinson, Cardiff,
UK; Wilkinson and Akrigg, 1992), in 1ml of medium, rocking the
flask every 20min. After 2h the infection medium was removed
and replaced with 12ml of fresh medium. After 48h, cells were
harvested for Western blot analysis of NR expression, or treated
with CB1954 prior to analysis of cell death.
Flow cytometric analysis of cell viability
Cells were plated out at a density of 2 10
5 cellsml
 1 in 48-well
plates and allowed to attach overnight. Following treatment with
either CB1954 or chemotherapeutic drugs for 48h, cells were
trypsinised and resuspended in 0.5ml saline (prewarmed to 371C).
Syto 16 (Molecular Probes Europe, Leiden, Netherlands) was
added at a concentration of 25nM and incubated with the cells at
room temperature for one 1h, at which time 5mgml
 1 propidium
iodide was added. Samples were analysed immediately on a
Coulter EPICS XL flow cytometer. A two-dimensional dot plot was
generated of Syto 16 fluorescence vs propidium iodide fluores-
cence. Syto 16 is only taken up by viable cells and propidium
iodide only enters cells whose membranes have become permea-
blised, therefore this technique distinguishes between viable cells
(syto 16 þve, propidium iodide  ve), apoptotic cells (syto 16
 ve, propidium iodide  ve) and necrotic cells (syto 16  ve,
propidium iodide þve) (Schuurhuis et al, 1997). Data for 10
4 cells
were collected for each sample and prior to data collection cell
debris was excluded by setting a gate on a forward vs side scatter
two-dimensional dot plot.
Caspase inhibitors
The cell-permeable caspase inhibitors IETD-FMK, LEHD-FMK,
DEVD-FMK and ZVAD-FMK (Calbiochem, UK) were added to
cells for 1h prior to treatment with either CB1954 or chemother-
apeutic drugs. Initially, a range of concentrations (1–200mM) was
tested and from these experiments a concentration of 50mM was
chosen for experiments in this study.
MTT assay
Cells were plated out at a density of 5 10
4 cellsml
 1 in 96-well
plates and allowed to attach overnight prior to treatment.
Following treatment, 20mlo f1 0 m g m l
 1 MTT (3-(4,4-di-
methylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (Sigma) in
PBS were added to each well and incubated for 4h at 371C, and the
formazan crystals formed were dissolved in DMSO. The absor-
bance was recorded at 550nm.
Analysis of the cytotoxic effect of CB1954 in combination
with other chemotherapeutic agents
The effect of drug combinations was calculated according to the
median effect principle described by Chou and Talalay (1984).
Firstly, the dose–response curves for the cytotoxic effects of
CB1954 and a panel of other drugs (cisplatin, 5-fluorouracil (5-
FU), topotecan, doxorubicin, paclitaxel, gemcitabine) in SKOV3
cells either stably expressing NR, or expressing NR delivered by an
adenovirus vector, for each agent singly and in combination were
constructed.
The median effect principle of mass action states that
fa=fu ¼ð D=DmÞm
where D is the drug dose, Dm the drug dose required for 50% cell
kill, fa the cell fraction affected, fu the cell fraction unaffected, and
m the coefficient of sigmoidicity.
This equation can be linearised by taking logarithms of both
sides so that y¼log(fa/fu) is plotted with respect to x¼log(D).
From this, m and Dm can be derived. Note that the linear
correlation coefficient, r, describes the conformity of the data to
the median effect principle. These data can then be used to
determine the ‘combination index’ (CI), using the equation:
CI ¼ð DÞ1=ðDxÞ1 þð DÞ2=ðDxÞ2
where (D)1 and (D)2 in combination kill x% of cells, and (Dx)1
and (Dx)2 are the doses of each drug alone that kill x% of cells.
If CI o1, ¼1o r41, then synergism, additive effect or
antagonism is indicated, respectively. So, if the combined observed
effect is greater than the calculated additive effect, synergism is
indicated.
The validity of this methodology was demonstrated by
confirmation of the previously reported synergistic interaction
between cisplatin and 5-FU (data not shown) (Shirasaka et al,
1993; Tsai et al, 1993).
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sRESULTS
The mode of cell death induced by CB1954 is
predominantly apoptosis
The SKOV3 ovarian carcinoma cell line was either selected to
stably express NR after retroviral transduction or infected with
RAd-NR to produce transient NR expression. A comparison of the
levels of NR expression showed that RAd-NR was able to deliver
NR in a dose-dependent manner successfully with a virus dose of
moi 10 resulting in similar levels of NR expression to that seen in
the stably expressing cell line (Figure 1A). Further, NR sensitised
SKOV3 cells to the prodrug CB1954 as measured by MTT assay,
the amount of cell death correlating with the level of NR expression
(Figure 1B).
Parental SKOV3 cells and SKOV3NR cells were treated with
CB1954 over a range of concentrations. After 48h, FACS analysis
was performed to determine the degree of cell death induced and
the relative amounts of apoptosis and necrosis. Figure 2B
demonstrates that the mode of cell death induced by activated
CB1954 in this setting was predominantly apoptosis, in common
with a range of other chemotherapeutic agents (data not shown
and Milner et al, 2002). In addition, RAd-NR infected SKOV3 cells
were treated with CB1954 and similar analysis was performed. This
confirmed that apoptosis was the predominant form of cell death
induced and that the degree of apoptosis increased in proportion
with increasing NR expression and increasing CB1954 dose (Figure
2C and D). In the absence of NR, CB1954 was toxic only at very
high concentration (Figure 2A).
Activated CB1954 initiates activation of caspase-8, -9
and -3
Stably expressing SKOV3NR cells were treated with a panel of
drugs commonly used in the treatment of ovarian cancer and with
CB1954 at doses sufficient to induce apoptosis in approximately
70% of the cells. Western blot analysis for caspase-8, -9, and -3
revealed that the active form of each caspase could be clearly
detected following treatment with all drugs including activated
CB1954 (Figure 3A). However, in the absence of NR, CB1954 was
unable to initiate apoptosis or activate any of these caspases
(Figure 3A).
SKOV3 cells transiently expressing NR were also treated with
CB1954 to induce high levels of apoptosis and similar Western
blots were performed. Again, activation of caspase-8, -9, and -3
was seen. RAd-NR infection alone or CB1954 treatment of cells
infected with a control adenovirus vector did not result in
apoptosis or caspase activation (Figure 3B).
The relative contribution of caspases to the induction
of apoptosis differs between RAd-NR infected and stable
NR-expressing cells treated with CB1954, and between
CB1954 and other chemotherapeutic agents
To determine whether the caspase activation seen in Figure 3
is essential for the mechanism of CB1954 induced cell death,
stably expressing SKOV3NR cells were treated with CB1954
or one of a range of other drugs either in the presence or
absence of specific inhibitors of caspase-3, -8, or -9, or a broad-
spectrum caspase inhibitor, ZVAD-FMK. We have previously
shown that at a concentration of 50mM, DEVD-FMK (caspase-3
inhibitor), IETD-FMK (caspase-8 inhibitor) and LEHD-FMK
(caspase-9 inhibitor) work in a specific manner (Milner et al,
2002). Therefore, this concentration was used for all the
inhibitors in these experiments. Figure 4 shows the levels
of cell death induced at 48h by either drugs alone or when
cells were preincubated with the inhibitors for 1h prior to drug
treatment.
Pretreatment with the broad-spectrum ZVAD inhibited
apoptosis induced by activated CB1954 or by the other drugs
used, confirming that apoptosis was caspase-dependent. In
addition, pretreatment with each of the specific caspase inhibi-
tors alone resulted in a significant reduction in the level of
apoptosis induced by all the conventional cytotoxic drugs
(Figure 4C, D and data not shown). However, pretreatment of
stably expressing SKOV3NR cells with individual inhibitors
alone was not sufficient to decrease CB1954-induced apoptosis,
although this was significantly reduced by a combination of
caspase-8 and -9 inhibitors. Apoptosis induced by CB1954 after
RAd-NR infection was again inhibited by ZVAD. However,
in this setting, the specific caspase-9 inhibitor (but not the
caspase-8 inhibitor) also resulted in a partial reduction in the
level of apoptosis, although a more profound inhibition
resulted from combined pretreatment with caspase-8 and -9
inhibitors.
Combination treatment with CB1954 plus 5-FU causes
enhanced tumour cell kill
As the above experiments indicated that apoptotic pathways and,
specifically, the relative contribution of caspases activated by
CB1954 differ from those initiated by other cytotoxic agents, it was
of interest to determine whether combining CB1954 with any of
these agents could cause an increase in cell death.
Stably expressing SKOV3NR cells were treated with CB1954
simultaneously with one of 5-FU, cisplatin, topotecan, doxorubi-
cin, paclitaxel or gemcitabine over a range of drug concentrations.
After 48h, cell viability was assessed using the MTT assay. These
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Figure 1 A replication-deficient adenovirus vector carrying the gene
encoding bacterial NR results in NR expression and sensitisation to
CB1954 cytotoxicity in SKOV3 cells. (A) SKOV3 cells were infected with
RAd-NR and the presence of NR protein was assessed 48h later by
Western blot analysis. Lane 1, mock infection; lane 2, control virus (RAd-
35) moi 100; lane 3, RAd-NR moi 1; lane 4, RAd-NR moi 10; lane 5, RAd-
NR moi 100; lane 6, stable NR-expressing SKOV3. (B) SKOV3 cells were
mock infected, infected with control virus or with RAd-NR (moi 1, 10,
100). After 48h, cells were treated with CB1954 over a range of doses (0,
0.1, 1, 10, 100 or 1000mM). SKOV3 cells stably expressing NR were
similarly treated. After a further 48h, cell viability was assessed by MTT
assay. Results are expressed as a percentage of the absorbance of
untreated cells and are the mean of three separate experiments 7s.e.
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combinations were synergistic, additive or antagonistic. It was
demonstrated that CB1954 in combination with 5-FU produced a
synergistic enhancement of cell killing over a wide range of drug
concentrations in both SKOV3NR cells and SKOV3 cells infected
with RAd-NR. Of note, in the absence of NR, CB1954 did not
potentiate 5-FU cytotoxicity. The addition of cisplatin, topotecan,
doxorubicin, paclitaxel or gemcitabine to CB1954 resulted in, at
best, additive cell killing and in some cases was even antagonistic
(Figure 5 and data not shown). Similar results, specifically
demonstrating synergy between activated CB1954 and 5-FU, have
been obtained in human colon cancer cell lines (WiDr and SW480,
data not shown).
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Figure 2 Analysis of the mode of cell death induced by activated
CB1954. SKOV3 cells were infected with RAd-NR and then treated with
CB1954 as described in Figure 1. The proportion of apoptotic and necrotic
cell death was determined by FACS analysis. Results are the mean of three
separate experiments 7s.e. (A) Parental SKOV3, no NR expression; (B)
SKOV3 cells stably expressing NR; (C) RAd-NR moi 1; (D) RAd-NR
moi 10.
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Figure 3 Caspase cleavage by activated CB1954. (A) SKOV3 and stable
NR expressing SKOV3 cells were treated with CB1954, cisplatin or 5-
fluorouracil at doses sufficient to cause apoptosis in approximately 70% of
cells (confirmed on samples prepared in parallel and analysed by FACS,
data not shown). The dose of CB1954 used to treat parental SKOV3 cells
was that which induced 70% apoptosis in NR-expressing cells. At this dose,
no apoptosis was observed in the parental cells. After 48h, the activation of
caspase-3, -8 and -9 was assessed by Western blot analysis. Antibodies able
to recognise both proform and active form of each caspase were used.
Lanes 1–4, parental SKOV3 cells; lanes 5–8, stable NR expressing cells.
Lanes 1 and 5, no drug; lanes 2 and 6, CB1954 10mM; lanes 3 and 7,
cisplatin 10mM; lanes 4 and 8, 5-FU 500mM.( B) SKOV3 cells were infected
with RAd-NR (moi 10) or control adenovirus, RAd-35 (moi 10). After 48h,
cells were treated with CB1954 10mM. After a further 48h, caspase
cleavage was assessed as in (A). Lane 1, untreated control; lane 2, CB1954
alone; lane 3, RAd-35þCB1954; lane 4, RAd-NR alone; lane 5, RAd-
NRþCB1954.
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sDISCUSSION
In this study, we have investigated the mechanism of cell death
induced by the VDEPT combination of NR and CB1954 in ovarian
carcinoma cells and have demonstrated a synergistic interaction
between activated CB1954 and 5-FU.
In common with a range of cytotoxic drugs with
diverse mechanisms of action, cell death induced by activated
CB1954 was predominantly apoptotic rather than necrotic.
This distinction is important as it is thought that apoptotic
cell death may not be optimal in generating immune
responses to tumour antigens, which might enhance
tumour cell killing in vivo (Melcher et al, 1999; Steinman
et al, 2000). So, immune-mediated bystander killing in vivo
may be enhanced by combined NR/CB1954 gene therapy
with immunostimulatory molecules such as GM-CSF (Green
et al, 2003).
Apoptosis induced by activated CB1954 was dependent
upon caspase activation as indicated by the effect of the
broad-spectrum caspase inhibitor, ZVAD. However, the relative
contribution of caspases to CB1954-induced apoptosis differed
from other cytotoxic drugs. Thus, inhibition of either caspase-3,
-8 or -9 alone was effective in reducing levels of apoptosis
induced by all the conventional cytotoxic drugs tested suggest-
ing that these are critical effectors of apoptosis. However,
when CB1954 was activated in cells stably expressing
NR, although caspase-3, -8 and -9 were cleaved, inhibition
of either one alone was not sufficient to block apoptosis.
Inhibition of caspase-8 and -9 together did significantly
reduce apoptosis. This indicates that activated CB1954 may
activate caspase-8 and -9 separately, either one of which is
sufficient for apoptosis, rather than caspase-9 cleavage occurring
downstream of caspase-8 via bid cleavage, as reported for
other apoptotic stimuli. This is consistent with previous
reports indicating that deficiency of certain caspases can result
in compensatory activation of alternative caspase pathways,
suggesting a degree of redundancy in death activating pathways
(Zheng et al, 2000).
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Figure 4 Effect of caspase inhibitors on CB1954-induced cell death.
SKOV3 cells stably expressing NR (A), or infected with RAd-NR moi 10
(B), were treated with CB1954 10mM in the presence or absence of a
broad-spectrum caspase inhibitor (ZVAD-FMK, 50mM), a caspase-3 like
inhibitor (DEVD-FMK, 50mM), a caspase-8-like inhibitor (IETD-FMK, 50mM)
or a caspase-9 like inhibitor (LEHD-FMK, 50mM). SKOV3 cells were treated
with cisplatin (10mM) or 5-FU (500mM) also in the presence or absence of
caspase inhibitors (C) and (D). The levels of cell death were analysed 48h
later by FACS. Results are the mean of three independent experiments
7s.e.
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Figure 5 Analysis of cytotoxicity induced by CB1954 in combination
with other chemotherapeutic agents. Cell viability in response to treatment
with drug combinations was assessed by MTT assay and results expressed
as a percentage of the absorbance of untreated cells (solid line; mean of
three experiments 7s.e.). The expected effect of each drug combination
based on an additive interaction was calculated (broken line). Therefore,
synergistic interactions will be to the left and antagonistic interactions to the
right of calculated curve. (A) Stable NR expressing SKOV3 cells were
treated with CB1954 over a range of doses (0–1000mM), in combination
with 5-FU in a fixed dose ratio (1:100) according to the median effect
principle of mass action. After 48h, cell viability was assessed by MTT. (C)
CB1954 in combination with cisplatin (dose ratio 1:1). (D) CB1954 in
combination with paclitaxel (dose ratio 10:1). (B) SKOV3 cells were
infected with RAd-NR (moi 1) and 48h later treated as in (A). All results
are the mean of three independent experiments 7s.e. The combination
index is also shown for each drug combination, where a value of
1¼additive, o1¼synergistic and 41¼antagonistic.
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was delivered via an adenovirus vector, with caspase-9 inhibition
resulting in a partial reduction in apoptosis. This may be
explained by the effect of the adenovirus vector upon anti-
apoptotic cellular pathways. Indeed, we have demonstrated
that such vectors activate the NF-kB pathway which in turn
upregulates expression of antiapoptotic cellular pathways
(manuscript submitted). Other studies have reported that
NF-kB inducible factors can act by inhibiting caspase-8 activity
downstream of its cleavage to the active form (Wang et al, 1998;
You et al, 2001). Therefore, the adenovirus vector may activate
cellular pathways resulting in caspase-8 inhibition, so that the
additional inhibition of caspase-9 may reduce CB1954-induced
apoptosis. These effects may be important, since adenovirus
delivery of prodrug-activating enzymes or other cytotoxic
agents is a major focus of cancer gene therapy protocols. These
data will prove useful in the further development of this novel
therapy and will facilitate the rational study of NR/CB1954 in
combination with other novel anticancer strategies or with
conventional chemotherapy.
The current study has addressed the effect of CB1954 given in
combination with other drugs to investigate whether potentially
synergistic combinations could be identified.
Using the median effect principle of mass action, it was
possible to calculate the expected effect of a combination of
drugs based on knowledge of their individual effects. This was
then compared to the observed effect achieved by the drug
combination. The ratio of the expected to the observed effect is the
‘CI’ so that CIo1 indicates a synergistic interaction, CI¼1
indicates an additive effect and CI41 indicates antagonism.
CB1954 treatment of SKOV3 cells stably expressing NR in
combination with cisplatin, topotecan, doxorubicin, paclitaxel or
gemcitabine demonstrated at best additive and in some cases even
antagonistic interaction. Conversely, the combination of CB1954
with 5-FU was found to be synergistic across a wide range of doses.
This effect was observed whether NR was expressed stably or
delivered via an adenovirus vector. These data suggest that, if
VDEPT is to be used in combination with conventional
chemotherapy, the clinical outcome may be critically dependent
upon the drugs chosen. As early phase clinical trials of other
VDEPT systems or conditionally replicating adenoviruses in
combination with conventional chemotherapy have reported this
to be a safe, feasible approach with promising evidence of efficacy,
the data presented here will prove useful in the rational design of
future clinical trials of VDEPT using NR/CB1954 (Khuri et al,
2000).
It will also be important to carry out further research to
determine why NR/CB1954 can synergise with some drugs, but
have an inhibitory effect with others. Since there are differences in
the pathways upstream of caspase cleavage activated by drugs with
different intracellular targets, this may determine the interaction of
drug combinations. Alternatively, synergy may be related to effects
on cell cycle progression (given that 5-FU is a cell cycle-specific
drug), effects on mechanisms of drug resistance, interference with
activation/inactivation of active metabolites, effects on DNA repair
mechanisms or other undefined mechanisms.
REFERENCES
Bridgewater JA, Springer CJ, Knox RJ, Minton NP, Michael NP, Collins MK
(1995) Expression of the bacterial nitroreductase enzyme in mammalian
cells renders them selectively sensitive to killing by the prodrug CB1954.
Eur J Cancer 31A(13–14): 2362–2370
Chou TC, Talalay P (1984) Quantitative analysis of dose–effect relation-
ships: the combined effects of multiple drugs or enzyme inhibitors. Adv
Enzyme Regul 22: 27–55
Chung-Faye G, Palmer D, Anderson D, Clark J, Downes M, Baddeley J,
Hussain S, Murray PI, Searle P, Seymour L, Harris PA, Ferry D, Kerr DJ
(2001) Virus-directed, enzyme prodrug therapy with nitroimidazole
reductase: a phase I and pharmacokinetic study of its prodrug, CB1954.
Clin Cancer Res 7(9): 2662–2668
Djeha AH, Hulme A, Dexter MT, Mountain A, Young LS, Searle PF, Kerr DJ,
Wrighton CJ (2000) Expression of Escherichia coli B nitroreductase in
established human tumor xenografts in mice results in potent
antitumoral and bystander effects upon systemic administration of the
prodrug CB1954. Cancer Gene Ther 7(5): 721–731
Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC,
Leibson PJ, Kaufmann SH (1997) Comparison of apoptosis in wild-type
and Fas-resistant cells: chemotherapy-induced apoptosis is not depen-
dent on Fas/Fas ligand interactions. Blood 90(3): 935–943
Friesen C, Herr I, Krammer PH, Debatin KM (1996) Involvement of the
CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in
leukemia cells. Nat Med 2(5): 574–577
Fulda S, Los M, Friesen C, Debatin KM (1998a) Chemosensitivity of solid
tumor cells in vitro is related to activation of the CD95 system. Int J
Cancer 76(1): 105–114
Fulda S, Scaffidi C, Pietsch T, Krammer PH, Peter ME, Debatin KM (1998b)
Activation of the CD95 (APO-1/Fas) pathway in drug- and gamma-
irradiation-induced apoptosis of brain tumor cells. Cell Death Differ
5(10): 884–893
Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM (1997) The CD95 (APO-
1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells.
Cancer Res 57(17): 3823–3829
Fulda S, Strauss G, Meyer E, Debatin KM (2000) Functional CD95 ligand
and CD95 death-inducing signaling complex in activation-induced cell
death and doxorubicin-induced apoptosis in leukemic T cells. Blood
95(1): 301–308
Gamen S, Anel A, Lasierra P, Alava MA, Martinez-Lorenzo MJ, Pineiro A,
Naval J (1997) Doxorubicin-induced apoptosis in human T-cell leukemia
is mediated by caspase-3 activation in a Fas-independent way. FEBS Lett
417(3): 360–364
Green NK, McNeish IA, Doshi R, Searle PF, Kerr DJ, Young LS (2003)
Immune enhancement of nitroreductase-induced cytotoxicity:
studies using a bicistronic adenovirus vector. Int J Cancer 104(1):
104–112
Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, Gore M,
Ironside J, MacDougall RH, Heise C, Randlev B, Gillenwater AM, Bruso
P, Kaye SB, Hong WK, Kirn DH (2000) A controlled trial of intratumoral
ONYX-015, a selectively replicating adenovirus, in combination with
cisplatin and 5-fluorouracil in patients with recurrent head and neck
cancer. Nat Med 6(8): 879–885
Knox RJ (ed). (1998) Targeted Anti-cancer Therapies: are They ADEPT or
INEPT? Greenwich, United Kingdom: The University of Greenwich
Inaugural Lecture Series
Link Jr CJ, Levy JP, McCann LZ, Moorman DW (1997) Gene therapy for
colon cancer with the herpes simplex thymidine kinase gene. J Surg
Oncol 64(4): 289–294
McNeish IA, Green NK, Gilligan MG, Ford MJ, Mautner V, Young LS, Kerr
DJ, Searle PF (1998) Virus directed enzyme prodrug therapy for ovarian
and pancreatic cancer using retrovirally delivered E. coli nitroreductase
and CB1954. Gene Therapy 5(8): 1061–1069
Melcher A, Gough M, Todryk S, Vile R (1999) Apoptosis or necrosis
for tumor immunotherapy: what’s in a name? J Mol Med 77(12):
824–833
Micheau O, Solary E, Hammann A, Martin F, Dimanche-Boitrel MT (1997)
Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated
cytotoxicity. J Natl Cancer Inst 89(11): 783–789
Milner AE, Palmer DH, Hodgkin EA, Eliopoulos AG, Knox PG, Poole CJ,
Kerr DJ, Young LS (2002) Induction of apoptosis by chemotherapeutic
drugs: the role of FADD in activation of caspase-8 and synergy with
death receptor ligands in ovarian carcinoma cells. Cell Death Differ 9(3):
287–300
Ruiz-Ruiz MC, Lopez-Rivas A (1999) p53-mediated up-regulation of CD95
is not involved in genotoxic drug-induced apoptosis of human breast
tumor cells. Cell Death Differ 6(3): 271–280
Enzyme-prodrug-mediated cell death
DH Palmer et al
949
British Journal of Cancer (2003) 89(5), 944–950 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sSchuurhuis GJ, Oberink JW, Bontje PM, Broxterman HJ (1997) The PGP
specific combination Syto
s 16/PSC833 detects early apoptosisin CD34
positive progenitor cells. Exp Hematol 25: 754
Shirasaka T, Shimamoto Y, Ohshimo H, Saito H, Fukushima M (1993)
Metabolic basis of the synergistic antitumor activities of 5-fluorouracil
and cisplatin in rodent tumor models in vivo. Cancer Chemother
Pharmacol 32(3): 167–172
Steinman RM, Turley S, Mellman I, Inaba K (2000) The induction of
tolerance by dendritic cells that have captured apoptotic cells. J Exp Med
191(3): 411–416
Sun XM, MacFarlane M, Zhuang J, Wolf BB, Green DR, Cohen GM (1999)
Distinct caspase cascades are initiated in receptor-mediated and
chemical-induced apoptosis. J Biol Chem 274(8): 5053–5060
Tolomeo M, Dusonchet L, Meli M, Grimaudo S, D’Alessandro N, Papoff G,
Ruberti G, Rausa L (1998) The CD95/CD95 ligand system is not the
major effector in anticancer drug-mediated apoptosis. Cell Death Differ
5(9): 735–742
Tsai CM, Hsiao SH, Frey CM, Chang KT, Perng RP, Gazdar AF, Kramer BS
(1993) Combination cytotoxic effects of cis-diamminedichloroplatinu-
m(II) and 5-fluorouracil with and without leucovorin against human
non-small cell lung cancer cell lines. Cancer Res 53(5): 1079–1084
Villunger A, Egle A, Kos M, Hartmann BL, Geley S, Kofler R, Greil R (1997)
Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95)
ligand expression but occurs independently of Fas (Apo-1/CD95)
signaling in human T-acute lymphatic leukemia cells. Cancer Res
57(16): 3331–3334
Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin Jr AS (1998)
NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and
c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281(5383):
1680–1683
Weedon SJ, Green NK, McNeish IA, Gilligan MG, Mautner V, Wrighton CJ,
Mountain A, Young LS, Kerr DJ, Searle PF (2000) Sensitisation of
human carcinoma cells to the prodrug CB1954 by adenovirus
vector-mediated expression of E. coli nitroreductase. Int J Cancer
86(6): 848–854
Wilkinson GW, Akrigg A (1992) Constitutive and enhanced expression
from the CMV major IE promoter in a defective adenovirus vector.
Nucleic Acids Res 20(9): 2233–2239
You Z, Ouyang H, Lopatin D, Polver PJ, Wang CY (2001) Nuclear factor-
kappa B-inducible death effector domain-containing protein suppresses
tumor necrosis factor-mediated apoptosis by inhibiting caspase-8
activity. J Biol Chem 276(28): 26398–26404
Zheng TS, Hunot S, Kuida K, Momoi T, Srinivasan A, Nicholson DW,
Lazebnik Y, Flavell RA (2000) Deficiency in caspase-9 or
caspase-3 induces compensatory caspase activation. Nat Med 6(11):
1241–1247
Enzyme-prodrug-mediated cell death
DH Palmer et al
950
British Journal of Cancer (2003) 89(5), 944–950 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s